Results 51 to 60 of about 65,665,756 (179)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Severe fever with thrombocytopenia syndrome (SFTS) [PDF]

open access: yes, 2021
Severe fever with thrombocytopenia syndrome (SFTS), is an emerging infectious zoonotic disease caused by a new phlebovirus, namely Huaiyangshan banyangvirus (family Phenuiviridae, Bunyavirales).
Gliński, Zdzisław, Żmuda, Andrzej
core  

Association of IFN‐γ +874 T/A Polymorphism With COVID‐19 Susceptibility, Severity, and Inflammatory Response: A Case–Control Study From Southern Iran

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Graphical abstract illustrating the association between IFN‐γ +874 T/A polymorphism and COVID‐19 outcomes. TA and AA genotypes are linked to increased susceptibility, higher inflammatory markers (notably IL‐6), greater disease severity, and longer hospitalization.
Nasir Arefinia   +4 more
wiley   +1 more source

Animal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection

open access: yesFrontiers in Microbiology, 2022
Severe fever with thrombocytopenia syndrome (SFTS), an emerging life-threatening infectious disease caused by SFTS bunyavirus (SFTSV; genus Bandavirus, family Phenuiviridae, order Bunyavirales), has been a significant medical problem.
Jiawen Sun   +12 more
doaj   +1 more source

Epidemiologic features of severe fever with Thrombocytopenia Syndrome in China, 2011-2012

open access: yes, 2013
Severe fever with thrombocytopenia syndrome (SFTS), an emerging vector-borne disease, is caused by a novel bunyavirus belonging to the genus Phlebovirus [1, 2].
Magalhaes, Ricardo J. Soares   +15 more
core   +1 more source

Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care

open access: yesPediatric Investigation, EarlyView.
This review presents a bedside framework for recognizing pediatric hemophagocytic lymphohistiocytosis and cytokine storm, stabilizing organ dysfunction, identifying the underlying phenotype, selecting targeted immunomodulation, considering extracorporeal adjuncts, and reassessing response within 24–72 h. ABSTRACT Hemophagocytic lymphohistiocytosis (HLH)
Weerapong Lilitwat, Prakreeti Bhandari
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy